A
Anat Loewenstein
Researcher at Tel Aviv Sourasky Medical Center
Publications - 443
Citations - 12603
Anat Loewenstein is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 50, co-authored 406 publications receiving 9997 citations. Previous affiliations of Anat Loewenstein include Johns Hopkins University & Westmead Hospital.
Papers
More filters
Journal ArticleDOI
SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
Elad Moisseiev,Gabriel Katz,Joseph Moisseiev,Anat Loewenstein,Michaella Goldstein,Yosef Lomnicky,Yitzhak Abend,Giora Treister,Dafna Goldenberg,Hana Levkovitch-Verbin +9 more
TL;DR: Switching to ranibizumab should be considered in patients with visual acuity decrease or CRT increase, despite monthly bevacizUMab injections, despite the response should be evaluated after the first three injections to guide future treatment.
Journal ArticleDOI
The rate of myocardial infarction events among patients with age-related macular degeneration: a population-based study.
Shani Golan,Shani Golan,Varda Shalev,Varda Shalev,Michaela Goldstein,Michaela Goldstein,Giora Treister,Giora Treister,Gabriel Chodick,Gabriel Chodick,Anat Loewenstein,Anat Loewenstein +11 more
TL;DR: Despite the shared risk factors associated with AMD and MIs, it is found that there is no increased risk of MI in AMD patients.
Journal ArticleDOI
Erectile dysfunction is associated with severe retinopathy in diabetic men.
Oren Henis,Yonathan Shahar,Arie Steinvil,Arie Steinvil,Talya Finn,Talya Finn,Rafi Heruti,Anat Loewenstein,Dan Justo +8 more
TL;DR: In this article, the association between sexual dysfunction and diabetic retinopathy with relation to DR severity levels has been studied, and significant ED is associated with DR severity independent of age, diabetes duration, macrovascular comorbidities, and cardiovascular risk factors.
Journal ArticleDOI
Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies.
TL;DR: In cases of uveitis, CME resolution is rapid, resulting in the longest effect duration, when compared with other CME etiologies, and DEX-DDS is beneficial in the treatment of persistent CME.
Journal ArticleDOI
Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study.
TL;DR: HA (20 µM) was found to be effective and safe in preventing the development of inflammation and TRD and damaged photoreceptors were evident after injection of high but not of low doses of HA.